Modality
mRNA
MOA
C5i
Target
MET
Pathway
Autophagy
MCL
Development Pipeline
Preclinical
Feb 2022
→ Sep 2026
PreclinicalCurrent
NCT06425442
2,464 pts·MCL
2022-02→2026-09·Completed
2,464 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-09-156mo awayInterim· MCL
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2026-09-15 · 6mo away
MCL
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06425442 | Preclinical | MCL | Completed | 2464 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| RAP-2478 | Rapport Ther | Phase 3 | MET | |
| Mavuzasiran | Protagonist | Phase 3 | MET | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |